Altimmune, Inc. (NASDAQ:ALT) Shares Purchased by Bellevue Group AG

Bellevue Group AG grew its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 9.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 945,446 shares of the company's stock after buying an additional 81,786 shares during the quarter. Bellevue Group AG owned about 1.33% of Altimmune worth $6,817,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Ameriprise Financial Inc. increased its holdings in Altimmune by 35.6% during the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock valued at $37,888,000 after acquiring an additional 1,378,854 shares in the last quarter. Invesco Ltd. increased its stake in shares of Altimmune by 679.2% during the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after purchasing an additional 215,375 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Altimmune during the 3rd quarter worth approximately $674,000. Wells Fargo & Company MN raised its position in shares of Altimmune by 69.3% during the 4th quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock worth $1,554,000 after purchasing an additional 88,209 shares during the last quarter. Finally, Barclays PLC lifted its stake in Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after buying an additional 75,064 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Price Performance

NASDAQ:ALT traded down $0.20 during mid-day trading on Friday, reaching $5.60. The company's stock had a trading volume of 1,901,321 shares, compared to its average volume of 2,850,404. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16. The company's fifty day simple moving average is $5.09 and its two-hundred day simple moving average is $6.61. The stock has a market cap of $431.28 million, a P/E ratio of -3.61 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Sell-side analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALT has been the subject of a number of analyst reports. William Blair reissued a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, April 3rd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $20.83.

Insider Transactions at Altimmune

In other news, CFO Gregory L. Weaver bought 10,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.10% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.